Abstract:Background: Transplantation (HSCT) outcome is significantly inferior in AML patients (pts) who required 2 rather than 1 induction course to achieve CR1, with a higher relapse (RI) and lower leukemia-free (LFS) and overall survival (OS) and lower graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS). Aims: To allocate the best donor for HSCT in AML pts achieving CR1 after 2 inductions comparing matched related sibling donors (MSD) with 9-10/10 HLA compatible unrelated donors (UD) and non-T cell depleted haploidentical (Haplo) donors, respectively. Methods: This was a retrospective analysis including adult pts aged ≥18 years with AML undergoing HSCT while in CR1 achieved after 2 inductions during the period 2010-2020. Allografts were from MSD, UD or Haplo donors. Multivariate analysis (MVA) adjusting for potential confounding factors was performed using a Cox’s proportional-hazards regression model for main outcomes. Results: 1295 pts were included: MSD (n=428), UD 10/10 (n=554), UD 9/10 (n=135), Haplo (n=178). Median follow up was 48.4, 46.0,40.5 and 35.2 months, respectively. Median age was 52.1, 53.8, 52.2 and 49.5 years, respectively. The 4 groups did not differ with respect to pts’ gender, type of AML, cytogenetics, and performance status. Haplo transplants were performed more recently, with more BM grafts and lower frequency of pt CMV seropositivity. Post-transplant cyclophosphamide (PTCy) was the main anti GVHD prophylaxis in HSCT from Haplo donors, while in vivo T-cell depletion was more frequently used in transplants from UD. Myeloablative conditioning was less frequently used in transplants from UD and time from diagnosis to HSCT was shorter in transplants from MSD. Cumulative incidence of ANC >0.5x109/L at day 30 was 98.1%, 98.5%, 95.5% and 92.1%, respectively (global P value=0.03). Univariate analysis of 2- and 5-year outcomes after transplantation are given in Table 1. On MVA, acute (a) GVHD II-IV but not III-IV was higher in all groups compared to MSD: UD 9/10, HR=2.53; 95% CI 1.68-3.82, P<0.0001; UD 10/10, HR=1.96; 95% CI 1.42-2.69, P<0.0001 and Haplo HR=2.15; 95% CI 1.41-3.3, P=0.0004. Incidence of extensive chronic (c) GVHD was significantly higher in UD 9/10 (HR=2.52; 95% CI 1.55-4.11, P=0.0002) and UD 10/10 (HR=1.48; 95% CI 1.03-2.13, P=0.036) and cGVHD all grades was higher in UD 9/10 vs MSD (HR=1.77; 95% CI 1.26-2.49, P=0.0009), while it did not differ in Haplo transplants. Non-relapse mortality (NRM) was higher in HSCT from UD 10/10, 9/10 and Haplo donors compared with those from MSD (HR= 1.75; 95% CI 1.16-2.63, P= 0.007, HR =2.22; 95% CI 1.29-3.83, P= 0.004 and HR=2.53; 95% CI 1.47-4.34, P=0.0008), respectively. RI, LFS and OS did not differ significantly between donor types: RI HR=0.84, P=0.18; HR=0.9, P=0.59 and HR=0.76, P=0.17 in UD 10/10, UD 9/10 and Haplo vs MSD, respectively. LFS HR=1.02, P=0.87; HR=1.15, P=0.35 and HR=1.11, P=0.49 and OS HR=1.12, P=0.3, HR=1.27, P=0.14 and HR=1.33, P=0.081, respectively. Finally, GRFS was lower in HSCT from UD 9/10 (HR=1.56, 95% CI 1.20-2.03, P<0.001) but not in those from UD 10/10 (HR=1.13, P=0.22) and Haplo donors (HR=1.12, P=0.43) compared to MSD, respectively. Main cause of death in all groups was original disease, followed by infections, and GVHD. Image:Summary/Conclusion: In AML patients undergoing allogeneic transplantation in CR1 achieved after two induction courses which has been shown to be a poor prognostic factor, and those who do not have an MSD, HLA matched UD and Haplo donors are comparable alternatives. 40-50% of these pts achieved long term LFS.

Matched and Mismatched Unrelated Donor Versus Unmanipulated Haploidentical Donors for Hematopoietic Cell Transplantation in Acute Leukemia in Remission: A Pair Matched Analysis on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

[A comparison of clinical outcomes between HLA allele matched and 1 - 2 alleles mismatched unrelated allogeneic bone marrow transplantations].

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

T-cell-replete Haploidentical Transplantation Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: a Matched Pair Analysis.

Unmanipulated Haploidentical Versus Matched Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia in First Remission: a Retrospective Pair-Matched Comparative Study of the Beijing Approach with the EBMT Database.

Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study

Similar Outcomes of Allogeneic Hematopoietic Cell Transplantation from Matched Sibling Donor and Haploidentical Donor for Refractory/Relapsed Acute Myeloid Leukemia

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT

ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT

Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, A Eurocord and Alwp-Ebmt Study

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT

Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation

[A Novel Approach to HLA-mismatched Transplantation].

Treatment Of Acute Leukaemia With Unmanipulated Hla-Mis-Matched/Haploidentical Blood And Bone Marrow Transplantation

Impact of Abo Incompatibility on Patients' Outcome after Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia - A Report from the Acute Leukemia Working Party of the Ebmt

The Inferiority of G-PB to Rhg-Csf-mobilized Blood and Marrow Grafts As a Stem Cell Source in Patients with High-Risk Acute Leukemia Who Underwent Unmanipulated HLA-mismatched/haploidentical Transplantation: a Comparative Analysis